Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data ...

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data ...

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Curis in a research note on Tuesday, December 10th. Receive News & Ratings for Curis Daily ...